Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM | Zendy

Lars H. Lund | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM

Author(s) -

Lars H. Lund

Publication year - 2018

Publication title -

cardiac failure review

Language(s) - English

Resource type - Journals

eISSN - 2057-7559

pISSN - 2057-7540

DOI - 10.15420/cfr.2018.11.2

Subject(s) - ejection fraction , candesartan , heart failure , medicine , cardiology , observational study , charm (quantum number) , fraction (chemistry) , chemistry , angiotensin ii , physics , nuclear physics , blood pressure , organic chemistry

The newly defined category of heart failure (HF) with mid-range ejection fraction (HFmrEF; EF 40–49 %) is beginning to be characterised but little is known about the potential for treating it. Trials and observational studies suggest that standard therapy for HF with reduced ejection fraction (HFrEF; EF <40 %) may also offer some benefit to patients with EF ≥40 %; however, any difference between its effects on HFmrEF and true HF with preserved ejection fraction (HFpEF) have until now not been explored. This study summarises randomised trial data from the CHARM programme that suggest that candesartan may improve outcomes in HFmrEF

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research